Cue Biopharma, Inc., a biotechnology company operating within the Health Care sector, has recently disclosed a significant change in beneficial ownership through a Form 4/A filing. This filing, submitted by Lin Shao‑Lee, an executive at the company, details the acquisition of pre‑funded and common‑stock warrants as part of a private placement that concluded in early May 2026. The transaction, which received approval from Cue Biopharma’s board, involved the issuance of warrants with an exercise price set at approximately $11 per share. These warrants grant holders the right to purchase common stock and became exercisable on June 1, 2026, following a special meeting of stockholders.
Cue Biopharma, Inc. is primarily engaged in the discovery and development of medications targeting cancers and autoimmune diseases. The company’s focus is on the design and clinical development of protein biologics, immunology, and immuno-oncology. Operating out of Massachusetts, Cue Biopharma serves a specialized customer base within this region.
As of July 30, 2026, the company’s close price was recorded at $26.84. Over the past year, the stock has experienced significant volatility, with a 52-week high of $45.5 on July 9, 2026, and a 52-week low of $4.98 on April 5, 2026. The market capitalization of Cue Biopharma stands at $112,740,000 USD. The company’s price-to-earnings ratio is currently -5.17, reflecting its financial performance and market valuation.
The recent Form 4/A filing serves to correct a previous transaction code and confirms the issuance of the warrants under applicable securities regulations. No further financial details beyond the nature of the warrants and their exercise terms were disclosed in the filing. This development is part of Cue Biopharma’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the biotechnology sector.
